[1]张旭桥,王晓晖,黄光明,等.生骨胶囊在经皮椎体强化术治疗老年骨质疏松性胸腰椎骨折中的应用研究[J].中医正骨,2016,28(11):21-25.
　ZHANG Xuqiao,WANG Xiaohui,HUANG Guangming,et al.Application of Shenggu Jiaonang(生骨胶囊)to the treatment of osteoporotic thoracolumbar vertebral fractures in the aged who received percutaneous vertebral augmentation[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(11):21-25.
点击复制

生骨胶囊在经皮椎体强化术治疗老年骨质疏松性胸腰椎骨折 中的应用研究()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第28卷
期数:
2016年11期
页码:
21-25
栏目:
临床研究
出版日期:
2016-11-20

文章信息/Info

Title:
Application of Shenggu Jiaonang(生骨胶囊)to the treatment of osteoporotic thoracolumbar vertebral fractures in the aged who received percutaneous vertebral augmentation
作者:
张旭桥; 王晓晖; 黄光明; 黄超文; 汤智; 徐洪祠; 李超
湖南省湘潭市中医医院,湖南 湘潭 411100
Author(s):
ZHANG Xuqiao; WANG Xiaohui; HUANG Guangming; HUANG Chaowen; TANG Zhi; XU Hongci; LI Chao
Xiangtan Hospital of Traditional Chinese Medicine,Xiangtan 411100,Hunan,China
关键词:
脊柱骨折;  骨质疏松性骨折;  生骨胶囊;  椎体成形术;  椎体后凸成形术;  临床试验
Keywords:
spinal fractures;  osteoporotic fractures;  Shenggu Jiaonang;  vertebroplasty;  kyphoplasty;  clinical trial
摘要:
目的:观察在常规经皮椎体强化术的基础上应用生骨胶囊治疗老年骨质疏松性胸腰椎骨折的临床疗效和安全性。方法:将符合要求的90例老年骨质疏松性胸腰椎骨折患者随机分为生骨胶囊组、阿法骨化醇组及椎体强化组,每组30例。3组患者均采用椎体强化术治疗,并于术后24 h开始口服阿仑膦酸钠片,每天10 mg,连服8周。在此基础上,生骨胶囊组自手术当天开始口服生骨胶囊,每次5粒,每天3次,连续服用8周; 阿法骨化醇组自手术当天开始口服阿法骨化醇胶丸,每次1粒,每天1次,连续服用8周。治疗期间定期检查血、尿、大便常规及肝肾功能、血清钙磷浓度、心电图,并观察并发症发生情况。采用视觉模拟评分量表(visual analogue scale,VAS)评定患者的疼痛程度,定期拍摄胸腰椎正侧位X线片观察骨折椎体压缩程度,采用超声波骨密度检测仪测定患者的跟骨骨密度,并采用自拟的疗效标准评定综合疗效。结果:所有患者均按要求完成了8周的治疗,至术后6个月时生骨胶囊组和椎体强化组各有7例失访,阿法骨化醇组有8例失访。3组患者均未发生腰肌血肿、神经根损伤、感染等并发症,至术后8周时阿法骨化醇组5例出现高血钙。术前及术后1 d 时3组患者的疼痛VAS评分比较,组间差异均无统计学意义(F=0.364,P=0.696; F=0.256,P=0.768)。术后8周、6个月时3组患者的疼痛VAS评分比较,组间差异均有统计学意义(χ2=39.741,P=0.000; χ2=55.852,P=0.000); 进一步两两比较,术后8周、6个月时生骨胶囊组和阿法骨化醇组的VAS评分比较,差异均无统计学意义(χ2=335.000,P=0.091; χ2=200.000,P=0.080); 生骨胶囊组和阿法骨化醇组的VAS评分均低于椎体强化组(χ2=59.000,P=0.000,χ2=79.000,P=0.000; χ2=20.000,P=0.000,χ2=30.000,P=0.000)。术后1 d、8周、6个月时3组患者的椎体压缩程度比较,组间差异均无统计学意义(χ2=0.228,P=0.892; χ2=0.007,P=0.996; χ2=2.695,P=0.260)。术后8周、6个月时3组患者的跟骨骨密度比较,组间差异均无统计学意义(χ2=2.618,P=0.270; χ2=3.317,P=0.190)。术后8周、6个月时生骨胶囊组、阿法骨化醇组的综合疗效均优于椎体强化组,生骨胶囊组的综合疗效均优于阿法骨化醇组(R^-生骨胶囊组=39.78,R^-阿法骨化醇组=41.07,R^-椎体强化组=55.65,χ2=9.328,P=0.009; R^-生骨胶囊组=27.46,R^-阿法骨化醇组=30.69,R^-椎体强化组=45.20,χ2=13.309,P=0.001)。结论:对老年骨质疏松性胸腰椎骨折,在常规经皮椎体强化术治疗的基础上应用生骨胶囊可进一步提高临床综合疗效,效果优于联合应用阿法骨化醇,而且具有较高的安全性。
Abstract:
Objective:To observe the clinical curative effect and safety of combination of oral application of Shenggu Jiaonang(SGJN,生骨胶囊)with conventional percutaneous vertebral augmentation for the treatment of osteoporotic thoracolumbar vertebral fractures in the aged.Methods:Ninety aged patients with osteoporotic thoracolumbar vertebral fractures were enrolled in the study and randomly divided into SGJN group,alfacalcidol group and vertebral augmentation group,30 cases in each group.All of the patients were treated with percutaneous vertebroplasty or percutaneous kyphoplasty,and were treated with oral application of alendronate sodium tablets since the 24th hour after the begining of the surgery,10 mg a day for 8 consecutive weeks.Meanwhile,the patients in SGJN group were treated with oral application of SGJN since the day of surgery,5 pills at a time,3 times a day for 8 consecutive weeks.The patients in alfacalcidol group were treated with oral application of alfacalcidol soft capsules since the day of surgery,1 pill at a time,once a day for 8 consecutive weeks.The blood RT,urine RT,stool RT,function of liver and kidney,serum contents of calcium and phosphorus and electrocardiogram were periodically examined during the treatment,meanwhile,the complications were observed.The pain degrees were evaluated by using visual analogue scale(VAS).The anteroposterior and lateral X-ray films of thoracolumbar spine were periodically scanned for assessing the degree of fractured vertebral bodies compression.The calcaneal bone mineral density(BMD)were measured by using ultrasonography machines.The general therapeutic effect were also evaluated by using self-made therapeutic effect standard.Results:All patients completed 8 weeks of treatment as required.Seven patients in SGJN group,7 patients in vertebral augmentation group and 8 patients in alfacalcidol group lost to follo-up by the 6th month after the surgery.No complications such as psoas hematoma,nerve root injury and infection were found in the 3 groups,while hypercalcemia(5 cases)were found in alfacalcidol group by the 8th week after the surgery.There was no statistical difference in pain VAS scores between the 3 groups before surgery and at 1 day after the surgery(F=0.364,P=0.696; F=0.256,P=0.768).There was statistical difference in pain VAS scores between the 3 groups at 8 weeks and 6 months after the surgery(χ2=39.741,P=0.000; χ2=55.852,P=0.000).Further pairwise comparison showed that there was no statistical difference in VAS scores between SGJN group and alfacalcidol group at 8 weeks and 6 months after the surgery(χ2=335.000,P=0.091; χ2=200.000,P=0.080),and.the VAS scores were lower in SGJN group and alfacalcidol group compared to vertebral augmentation group(χ2=59.000,P=0.000,χ2=79.000,P=0.000; χ2=20.000,P=0.000,χ2=30.000,P=0.000).There was no statistical difference in the degree of fractured vertebral bodies compression between the 3 groups at 1 day,8 weeks and 6 months after the surgery(χ2=0.228,P=0.892; χ2=0.007,P=0.996; χ2=2.695,P=0.260).There was no statistical difference in the calcaneal BMD between the 3 groups at 8 weeks and 6 months after the surgery(χ2=2.618,P=0.270; χ2=3.317,P=0.190).SGJN group and alfacalcidol group surpassed vertebral augmentation group and SGJN group surpassed alfacalcidol group in the general therapeutic effect at 8 weeks and 6 months after the surgery(R^-SGJN group=39.78,R^-alfacalcidol group=41.07,R^-vertebral augmentation group=55.65,χ2=9.328.P=0.009; R^-SGJN group=27.46,R^-alfacalcidol group=30.69,R^-vertebral augmentation group=45.20,χ2=13.309,P=0.001).Conclusion:Oral application of SGJN can improve general therapeutic effect of conventional percutaneous vertebral augmentation with high safety in treatment of osteoporotic thoracolumbar vertebral fractures in the aged,and the therapeutic effect of percutaneous vertebral augmentation in combination with SGJN is better than in combination with alfacalcidol.

参考文献/References:

[1] 韩亚军,帖小佳,伊力哈木·托合提,等.中国中老年人骨质疏松症患病率的Meta分析[J].中国组织工程研究,2014,18(7):1129-1134.
[2] 胥少汀,葛宝丰,徐印坎.实用骨科学[M].4版.北京:人民军医出版社,2012:465-470.
[3] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
[4] 郑筱萸.中药新药临床研究指导原则:试行[M].北京:中国医药科技出版社,2002:357.
[5] 蒋协远,王大伟.骨科临床疗效评价标准[M].北京:人民卫生出版社,2005:123-124.
[6] 廖二元,徐苓,朱汉民,等.原发性骨质疏松症干预的疗效监测与评估专家意见[J].中华骨质疏松和骨矿盐疾病杂志,2015,8(1):1-6.
[7] 全仁夫,倪月明,郑宣,等.经皮椎体成形术后骨折椎体生物力学性能和组织形态研究[J].中医正骨,2013,25(12):15-19.
[8] 陈书连,张广泉,高坤,等.经皮椎体成形术与椎体后凸成形术治疗骨质疏松性椎体骨折的疗效比较研究[J].中华实用诊断与治疗杂志,2009,23(10):953-956.
[9] 杨波,谢景开,尹飚,等.经皮椎体成形术治疗老年多节段骨质疏松性椎体压缩性骨折[J].中国矫形外科杂志,2012,20(24):2212-2216.
[10] 张绍东,姜星杰,吴小涛,等.三种骨水泥应用于椎体成形术的生物力学比较[J].中国脊柱脊髓杂志,2007,17(3):205-209.
[11] 何升华,马笃军,余伟吉,等.过伸牵引弹性按压法联合经皮椎体成形术治疗骨质疏松性胸腰椎压缩骨折的临床研究[J].中医正骨,2014,26(3):25-29.
[12] 李伟民,林志雄,张健荣.骨水泥注射微创治疗椎体病理性骨折的治疗体会[J].实用骨科杂志,2014,20(8):740-743.
[13] 陈安刚,曾本强,杨勇,等.经皮骨水泥注入椎体成形修复骨质疏松性胸腰椎压缩骨折[J].中国组织工程研究,2014,18(52):8371-8375.
[14] 王轩,潘琪,张慧萍,等.桃仁、木香、黄芪分别与红花配伍对大鼠早期桡骨骨折愈合过程中BMP-2表达的影响[J].中华中医药杂志,2011,26(6):1423-1425.
[15] 莫朝伦,张军梅,贾莹,等.丹参酮Ⅱ-A对大鼠成骨细胞体外增殖分化的影响[J].贵阳医学院学报,2016,41(4):391-394.
[16] 徐英杰,尹羽薇,肖正权,等.生骨胶囊对兔早期激素性股骨头坏死骨组织BMP-2、PPAR-γ表达影响的研究[J].中医药学报,2015,43(1):19-22.
[17] 聂红,沈映君,曾南,等.白芷总挥发油对疼痛模型大鼠的神经递质的影响[J].中药药理与临床,2002,18(3):11-14.

相似文献/References:

[1]邓红军.硫酸钙骨水泥椎体成形联合后路短节段椎弓根螺钉 内固定治疗创伤性胸腰椎骨折[J].中医正骨,2015,27(10):35.
[2]李鹏,徐世涛,谭磊.椎旁肌间隙入路伤椎单侧植骨内固定治疗 单节段胸腰椎骨折[J].中医正骨,2015,27(06):43.
[3]孙德舜,王小鹤,王晓燕,等.气囊托板复位配合骨伤复元汤口服治疗 胸腰椎单纯压缩骨折[J].中医正骨,2015,27(05):65.
[4]郭世明,石玲玲,郭志民,等.手法复位石膏外固定和切开复位钢板内固定治疗 骨质疏松性桡骨远端骨折的比较研究[J].中医正骨,2015,27(04):15.
　GUO Shiming,SHI Lingling,GUO Zhimin,et al.A comparative study of manual reduction and plaster external fixation versus open reduction and plate internal fixation for treatment of osteoporotic distal radius fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(11):15.
[5]武祥仁,胡海涛,茅祖斌.经椎旁肌间隙入路伤椎植骨内固定治疗 无神经损伤的胸腰椎骨折[J].中医正骨,2015,27(03):56.
[6]刘杰,朱小龙,石晨.手法复位联合经皮椎体后凸成形术治疗胸腰椎压缩性骨折[J].中医正骨,2016,28(05):28.
[7]杨振国,王树强,范杰,等.钉棒系统复位内固定联合经椎弓根撬拨植骨术治疗胸腰椎压缩性骨折[J].中医正骨,2016,28(05):31.
[8]陈思凯,邢金明.骨水泥强化椎弓根螺钉内固定治疗老年胸腰椎压缩性骨折[J].中医正骨,2016,28(05):35.
[9]徐无忌,刘晓岚.体位复位结合经皮椎体成形术与经皮椎体后凸成形术治疗骨质疏松性椎体压缩骨折的对比研究[J].中医正骨,2016,28(07):20.
　XU Wuji,LIU Xiaolan.Effect of Qianggu Yin(强骨饮,QGY)on bone microstructure in the ovariectomized osteoporosis rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(11):20.
[10]孙彦鹏,史相钦,马虎升,等.小开窗减压短力臂伤椎置钉复位内固定术治疗胸腰椎爆裂性骨折[J].中医正骨,2016,28(11):26.
[11]许兵,叶小雨,王萧枫,等.小管径经皮椎体后凸成形术治疗 骨质疏松性椎体重度压缩骨折[J].中医正骨,2015,27(11):29.
[12]谢小利,李晓程.经皮椎体后凸成形术治疗骨质疏松性椎体 压缩骨折的围手术期护理[J].中医正骨,2015,27(05):79.
[13]李格,梅伟,刘沛霖,等.骨质疏松性椎体压缩骨折经皮椎体成形术后邻近椎体再骨折的危险因素探讨[J].中医正骨,2016,28(06):18.
　LI Ge,MEI Wei,LIU Peilin,et al.Investigation on risk factors for adjacent vertebral refractures after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(11):18.
[14]张 涛.常规抗骨质疏松疗法联合脉冲射频术和银质针松解术治疗骨质疏松性椎体压缩骨折[J].中医正骨,2017,29(04):74.
[15]王建民,李华东,王振东.温针灸结合补阳还五汤口服治疗骨质疏松性椎体压缩骨折经皮椎体后凸成形术后残留痛[J].中医正骨,2017,29(11):69.
[16]罗科锋,蔡凯文,卢斌,等.矿化胶原-聚甲基丙烯酸甲酯骨水泥经皮椎体后凸成形术治疗Ⅰ、Ⅱ期Kmmell病的临床研究[J].中医正骨,2018,30(06):4.
　LUO Kefeng,CAI Kaiwen,LU Bin,et al.A clinical study of percutaneous kyphoplasty with mineralized collagen-polymethylmethacrylate bone cement for treatment of phaseⅠandⅡKmmell's diseases[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(11):4.
[17]王庆德,梅伟,张振辉,等.经椎弓根打压植骨与经后路椎体次全切除治疗Ⅲ期Kmmell病的对比研究[J].中医正骨,2018,30(06):15.
　WANG Qingde,MEI Wei,ZHANG Zhenhui,et al.A comparative study of transpedicular impaction bone grafting versus subtotal vertebrectomy through posterior approach for treatment of phaseⅢKmmell's diseases[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(11):15.
[18]陈雯,马俊明,莫文.骨水泥联合Genex人工骨经皮椎体后凸成形术治疗骨质疏松性胸腰椎压缩性骨折[J].中医正骨,2018,30(06):40.
[19]韩雷,全仁夫.后路短节段椎弓根螺钉内固定联合椎体成形术治疗Ⅲ期Kmmell病[J].中医正骨,2018,30(06):47.
[20]赖欧杰,胡勇,袁振山,等.伤椎椎体成形联合后路融合固定术治疗Ⅲ期Kmmell病[J].中医正骨,2018,30(06):70.

备注/Memo

备注/Memo:
基金项目:2014年度湖南省中医药科研计划项目(2014126)
通讯作者:张旭桥 E-mail:81219458@qq.com
更新日期/Last Update: 2016-11-30